Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration
Objective: The aim of the present study was to investigate the influence of apomorphine pump in Parkinson’s disease (PD) on motor and nonmotor symptoms, including…Stimulation in the nucleus entopeduncularis affects neuronal activity in the nucleus accumbens and medial prefrontal cortex after apomorphine-induced deficient prepulse inhibition in rats
Objective: The aim of our study was to investigate the effects of stimulation in the rat entopeduncular nucleus (EPN) on single neuronal activity of the…Apomorphine infusion does not impair cognitive action control in Parkinson’s disease
Objective: We sought to verify that apomorphine infusion did not alter cognitive action control.We sought to verify that apomorphine infusion did not alter cognitive action…Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment
Objective: The TOLEDO Study (NCT02006121) is a prospective, randomized, multicenter, double-blind, Phase III trial undertaken to investigate the efficacy of apomorphine subcutaneous infusion (APO) compared…Study Design of an Efficacy and Safety Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of APL-130277 in the Treatment of OFF Episodes (CTH-300)
Objective: To review the unique features of the ongoing Phase 3 trial for APL-130277. Background: Patients with Parkinson’s disease (PD) frequently develop problematic OFF episodes…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase
Objective: To determine the dose of APL-130277 required by each patient with Parkinson’s Disease (PD) to turn from OFF to Full ON. This dose is…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study
Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD). Background: Patients with Parkinson’s disease (PD) frequently develop problematic…Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study
Objective: To determine if baseline disease severity could be correlated to the effective dose of APL-130277 that was required to turn a patient with PD…ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data
Objective: To evaluate the PK and relative bioavailability of ND0701, a subcutaneously (SC) infused apomorphine-base product candidate, and a commercial apomorphine-HCl product. The secondary objective…Sensor based gait analysis: Diagnostic application for apomorphine titration
Objective: The goal of the present study was to quantify individual gait changes by eGaIT during the standardized titration test for subcutaneous apomorphine treatment. Background:…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- Next Page »